

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

CHANGE IN BOARD LOT SIZE

The board (the “**Board**”) of directors (the “**Directors**”) of Genscript Biotech Corporation (the “**Company**”) hereby announces that the board lot size of the Company’s issued ordinary shares (the “**Share(s)**”) trading on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) will be changed from 2,000 Shares (the “**Existing Board Lot Size**”) to 1,000 Shares (the “**New Board Lot Size**”) with effect from 9:00 a.m. on Wednesday, 14 October 2026 (the “**Change in Board Lot Size**”). The Change in Board Lot Size will not affect any of the relative rights of the Company’s shareholders (the “**Shareholders**”).

Based on the closing price of HK\$41.40 per Share as quoted on the Stock Exchange as at the date of this announcement, the market value of the Existing Board Lot Size is approximately HK\$82,800, and the market value of the New Board Lot Size is approximately HK\$41,400. The Change in Board Lot Size will directly reduce the value of each board lot by half, thereby lowering the minimum transaction value for trading of the Shares. The Board is of the view that the lower board lot value may make the Shares more accessible to a wider range of investors and facilitate trading of the Shares, which may in turn improve the liquidity of the Shares. Therefore, the Change in Board Lot Size is in the interests of the Company and the Shareholders as a whole.

As the New Board Lot Size is an integral divisor of the Existing Board Lot Size, no new odd lots of the Shares will be created as a result of the Change in Board Lot Size. Having consulted with the Share Registrar (as defined below), no odd lot arrangement or matching service for the sales and purchase of odd lots of the Shares will be made by the Company in connection with the Change in Board Lot Size.

EXPECTED TIMETABLE

The expected timetable for the Change in Board Lot Size is set out below, where all times and dates refer to Hong Kong local times and dates:

Event	Time and date
Publication of this announcement on the Change in Board Lot Size	Monday, 21 September 2026
First day for free exchange of the existing share certificates in board lots of 2,000 Shares for the new share certificates in board lots of 1,000 Shares	Tuesday, 29 September 2026
Last day for trading in the Shares in board lots of 2,000 Shares in the original counter	Tuesday, 13 October 2026
Effective date of the Change in Board Lot Size	Wednesday, 14 October 2026
Original counter for trading in the Shares in board lots of 2,000 Shares becomes counter for trading in the Shares in board lots of 1,000 Shares	9:00 a.m. Wednesday, 14 October 2026
Temporary counter for trading in the Shares in board lots of 2,000 Shares opens	9:00 a.m. Wednesday, 14 October 2026
First day of parallel trading in the Shares (in board lots of 1,000 Shares and 2,000 Shares)	9:00 a.m. Wednesday, 14 October 2026
Temporary counter for trading in the Shares in board lots of 2,000 Shares closes	4:10 p.m. Wednesday, 4 November 2026
Last day of parallel trading in the Shares (in board lots of 1,000 Shares and 2,000 Shares)	4:10 p.m. Wednesday, 4 November 2026
Last day for free exchange of the existing share certificates in board lots of 2,000 Shares for the new share certificates in board lots of 1,000 Shares	4:30 p.m. Friday, 6 November 2026

All dates or deadlines specified in the expected timetable above are indicative only and may be varied by the Company. Any consequential changes to this expected timetable will be notified to the Shareholders by way of announcement as and when appropriate.

FREE EXCHANGE OF SHARE CERTIFICATES

The Shareholders may submit their existing share certificates in board lots of 2,000 Shares to the Company's branch share registrar and transfer office, Computershare Hong Kong Investor Services Limited, located at Shops 1712–1716, 17/F, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (the "**Share Registrar**") in exchange for new share certificates in board lots of 1,000 Shares free of charge during business hours (i.e. 9:00 a.m. to 4:30 p.m.) from Tuesday, 29 September 2026 to Friday, 6 November 2026 (both days inclusive).

After the expiry of the aforesaid period, the existing share certificates will be accepted for exchange only upon payment of a fee of HK\$2.50 (or such higher amount as may from time to time be specified by the Stock Exchange) for each new share certificate issued in board lot of 1,000 Shares or each existing share certificate submitted, whichever number of share certificates involved is higher. It is expected that the new share certificates will be available for collection by the Shareholders from the Share Registrar within ten business days after delivery of the existing share certificates to the Share Registrar for exchange purposes.

As from Wednesday, 14 October 2026, any new share certificates will be issued in board lots of 1,000 Shares each (except for odd lots of the Shares or where the Share Registrar is otherwise instructed). All the existing share certificates in board lots of 2,000 Shares will continue to be evidence of legal title to such Shares and be valid for transfer, delivery and settlement purposes. Save and except for the change in the number of Shares represented by each board lot and the logo of the Company, the new share certificates will have the same form as the existing share certificates. The new share certificates will retain the same blue colour as the existing share certificates.

The Shareholders and potential investors of the Company should exercise caution when dealing in the Shares, and if they are in any doubt about their position, they should consult their professional advisers.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 21 September 2026

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng ("**Mr. Robin Meng**"), Dr. Fangliang Zhang ("**Dr. Frank Zhang**"), Dr. Li Zhu and Ms. Ye Wang ("**Ms. Sally Wang**"); and the independent non-executive Directors are Mr. Yiu Leung Andy Cheung ("**Mr. Andy Cheung**"), Mr. Jiuan Pan ("**Mr. Ethan Pan**"), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi ("**Dr. Victor Shi**").*